ADCI Stock Overview
Engages in the manufacture and sale of pharmaceutical products. More details
| Snowflake Score | |
|---|---|
| Valuation | 1/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 4/6 |
| Dividends | 4/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
The Arab Drug Company Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | ج.م179.79 |
| 52 Week High | ج.م186.50 |
| 52 Week Low | ج.م76.02 |
| Beta | 0.62 |
| 1 Month Change | 13.42% |
| 3 Month Change | 27.07% |
| 1 Year Change | 90.88% |
| 3 Year Change | 213.77% |
| 5 Year Change | 249.38% |
| Change since IPO | 1,344.76% |
Recent News & Updates
Recent updates
Shareholder Returns
| ADCI | EG Pharmaceuticals | EG Market | |
|---|---|---|---|
| 7D | 0.6% | -1.6% | -1.5% |
| 1Y | 90.9% | 54.2% | 32.2% |
Return vs Industry: ADCI exceeded the EG Pharmaceuticals industry which returned 53.2% over the past year.
Return vs Market: ADCI exceeded the EG Market which returned 31.2% over the past year.
Price Volatility
| ADCI volatility | |
|---|---|
| ADCI Average Weekly Movement | 7.7% |
| Pharmaceuticals Industry Average Movement | 5.6% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in EG Market | 8.4% |
| 10% least volatile stocks in EG Market | 3.1% |
Stable Share Price: ADCI's share price has been volatile over the past 3 months compared to the EG market.
Volatility Over Time: ADCI's weekly volatility (8%) has been stable over the past year, but is still higher than 75% of EG stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1963 | n/a | Tamer Mohamed Al-Hosseiny | www.adcopharma-eg.com |
The Arab Drug Company engages in the manufacture and sale of pharmaceutical products. It offers anti-infectives, central nervous system drugs, dermatological drugs, and cardiovascular drugs, as well as animal health products in powders and solutions. The company exports its products to approximately 40 countries, including China, Korea, Turkey, Kazakhstan, Iraq, Syria, Jordan, Lebanon, Libya, Sudan, Somalia, Yemen, and Morocco.
The Arab Drug Company Fundamentals Summary
| ADCI fundamental statistics | |
|---|---|
| Market cap | ج.م1.08b |
| Earnings (TTM) | ج.م122.99m |
| Revenue (TTM) | ج.م929.75m |
8.8x
P/E Ratio1.2x
P/S RatioIs ADCI overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| ADCI income statement (TTM) | |
|---|---|
| Revenue | ج.م929.75m |
| Cost of Revenue | ج.م579.68m |
| Gross Profit | ج.م350.08m |
| Other Expenses | ج.م227.08m |
| Earnings | ج.م122.99m |
Last Reported Earnings
Dec 31, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | 20.50 |
| Gross Margin | 37.65% |
| Net Profit Margin | 13.23% |
| Debt/Equity Ratio | 101.0% |
How did ADCI perform over the long term?
See historical performance and comparisonDividends
4.6%
Current Dividend Yield41%
Payout RatioCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/13 23:34 |
| End of Day Share Price | 2025/05/13 00:00 |
| Earnings | 2024/12/31 |
| Annual Earnings | 2024/06/30 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
The Arab Drug Company is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Mohamed Hamza | Pharos Research |